MedTrace Logo

Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer

NCT00902668 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2013-06-20

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs, such as lovastatin, may protect normal cells from the side effects of radiation therapy.

PURPOSE: This phase II trial is studying how well lovastatin works in reducing side effects after radiation therapy in women with breast cancer.

Conditions

Interventions

DRUG

lovastatin

OTHER

questionnaire administration

PROCEDURE

adjuvant therapy

RADIATION

accelerated partial breast irradiation

RADIATION

external beam radiation therapy

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Laurie W. Cuttino, MD · Massey Cancer Center

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-04-30
Completion
2013-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902668 on ClinicalTrials.gov